| Total Fund Raise | ₹46.98 CrCombined Issue |
|---|---|
| Market Cap | ₹586.25 CrSmall Cap |
| Revenue Growth | 76.76%Annual YoY |
| Issue Price | ₹518.55Per Share/Warrant |
| Deal value | ₹46.98 Cr |
| Share of market cap | 8.0% |
Key highlights
- Preferential issue of up to 3,86,000 equity shares at ₹518.55 each, aggregating to ₹20.01 crore
- Issuance of 5,20,000 fully convertible warrants at ₹518.55 each, totaling ₹26.96 crore
- Prominent non-promoter investor Ashish Rameshchandra Kacholia to be allotted 1,73,200 shares
- Extra-Ordinary General Meeting (EGM) to seek shareholder approval scheduled for October 16, 2026
- Warrant holders required to pay 25% upfront, with the balance 75% due upon exercise within 18 months
Details of the Preferential Allotment
The fund-raising exercise is bifurcated into two primary instruments. First, the company will issue 3,86,000 equity shares of face value ₹10 each at a premium of ₹508.55, totaling an issue price of ₹518.55 per share. This component targets 26 investors, including Ashish Rameshchandra Kacholia, who is slated to receive 1,73,200 shares.
Second, Qualitek Labs will issue 5,20,000 fully convertible warrants to TIC Services Private Limited, a promoter group entity. Each warrant is priced identically at ₹518.55 and carries the right to subscribe to one equity share within an 18-month tenure from the date of allotment.
Business and Financial Performance
Qualitek Labs operates within the commercial services and supplies sector, specifically providing testing, inspection, and certification services across automotive, food, water, and environmental segments. The company has demonstrated robust growth, with annual operating revenue reaching ₹124.52 crore and net profit climbing to ₹14.6 crore, representing a 131.74% year-on-year increase. Currently, the stock carries a high momentum score of 74.69 and has seen a 32.91% price change over the last month.
The issue price of ₹518.55 stands in relation to a current market price of ₹587.45 and a 1-year high of ₹628.5.
Strategic Rationale and Shareholding
- Capital infusion is intended to support the company's expansion in the Testing, Inspection, and Certification (TIC) sector.
- The allotment to the promoter group through warrants signals continued commitment from the core management team.
- Participation from 25 non-promoter investors diversifies the shareholding base and increases institutional interest.
- The 18-month warrant conversion window provides a phased approach to capital receipt, ensuring liquidity over the medium term.
- Proceeds will likely bolster the balance sheet, which currently shows a net cash flow of ₹1.24 crore.
Industry Context
The Indian TIC industry is witnessing a surge in demand driven by stringent environmental regulations and increasing quality standards across manufacturing sectors. With a sector revenue growth of 37.14% Qtr YoY, companies like Qualitek Labs are positioning themselves to capture market share through capacity building. The company’s current price-to-earnings (P/E) ratio of 40.15 sits slightly below the sector P/E of 42.14, reflecting a valuation aligned with industry peers in the consulting and technical services space.
| Share price | ₹587.45 |
|---|---|
| Market capitalisation | ₹586.25 Cr |
| Revenue (annual) | ₹124.52 Cr |
| Net profit (annual) | ₹14.60 Cr |
| P/E (TTM) | 40.15×Sector 42.14× |
| Promoter holding | 56.46% |
| FII holding | 1.6%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Qualitek Labs Ltd announcing the outcome of the Board meeting regarding the preferential issue of shares and warrants. Market figures from a third-party data provider.
